Description: Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies.
Home Page: www.siogtx.com
SIOX Technical Analysis
130 West 42nd Street
New York,
NY
10036
United States
Phone:
877 746 4891
Officers
| Name | Title |
|---|---|
| Mr. David W. Nassif J.D. | CEO, CFO, Chief Accounting Officer, Gen. Counsel & Director |
| Ms. Raquel Crystal | Head of HR & Operations |
| Dr. Guangping Gao Ph.D. | Chief AAV Scientific Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5419 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2015-06-11 |
| Fiscal Year End: | March |
| Full Time Employees: | 12 |